US Will Work With Foodmakers to Stop the Use of Synthetic Dyes
The US Department of Health and Human Services plans to phase out artificial food dyes by working with food companies that rely heavily on them to produce everything from breakfast cereal to salad dressing.
Food and Drug Administration Commissioner Marty Makary said Tuesday the agency would work with the industry to eliminate six synthetic dyes by the end of 2026, including Red 40, Yellow 5 and Blue 1. The FDA will also ask the industry to eliminate Red 3 before 2027, the timeline set by the Joe Biden administration.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Health New England to replace Humira coverage with lower-cost biosimilars
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 hours ago
- Yahoo
MemoDefend Announces Official Website Update Featuring Natural Daily Supplement for Cognitive Support
Natural Brain Health Formula Now Available Online to Support Memory, Focus, and Cognitive Function in Adults Lakeland, June 09, 2025 (GLOBE NEWSWIRE) -- MemoDefend, a Florida-based wellness brand, has updated its official website to provide consumers with new information about its daily supplement formulated to support cognitive clarity and brain function in adults. Now available nationwide, the natural memory support formula is designed for individuals seeking a consistent, easy-to-integrate wellness solution. According to the official product website ( MemoDefend is intended to work in harmony with the body's internal processes to support healthy memory retention, mental sharpness, and overall cognitive performance. The brand highlights its approach as one that simplifies brain wellness without requiring restrictive regimens or complicated routines. 'We developed MemoDefend to help adults support brain health naturally—without disrupting their lifestyle,' said a company spokesperson. 'This product reflects our focus on purity, simplicity, and long-term wellness.' The company states that MemoDefend is produced in facilities that follow strict quality control practices. Its formulation features a selection of ingredients that align with adult wellness priorities such as cognitive support, mental clarity, and healthy aging. As noted on the website, MemoDefend includes a satisfaction guarantee for new customers. Those interested in learning more about its intended use or placing an order can find full details, customer support access, and purchasing options directly at the official website. About MemoDefend MemoDefend is a Lakeland, Florida-based wellness brand committed to delivering natural, easy-to-use supplements that support everyday health routines. Focused on transparency and simplicity, the company develops formulas to help adults feel more confident in their wellness journey—one daily step at a time. Product and Contact Information Brand: MemoDefendWebsite: support@ +1 (888) 535-1590Mailing Address: P.O. Box 90129, Lakeland, FL 33804, United States Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: support@ Phone: +1 (888) 535-1590Sign in to access your portfolio
Medscape
4 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
